PATENT CLAIM ANALYSIS

Application Number: 16311979
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-07
Patent Classification: ["514", "249000"]

Abstract:
Imidazopyrazinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and/or treating indications/diseases associated with BTK functions are disclosed. The disclosed imidazopyrazinamine phenyl derivatives are ideal high-efficient BTK inhibitors for treating or preventing diseases such as rheumatoid arthritis, B cell lymphoma, leukemia, multiple myeloma, allergies, asthma, multiple sclerosis, type I diabetes and systemic lupus erythematosus.

Claim (Index 3):
The imidazopyrazinamine phenyl derivative according to  claim 1 , a pharmaceutically acceptable salt and hydrate thereof, or a metabolite thereof formed by any form of metabolism, wherein R 2  is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.41667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15109101', '14417588', '15987458', '14394787', '12989410']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.725827594171847
- 35 USC 102 Novelty (BERT): 0.5097206854877135
- Combined Prediction Score: 0.7042169033034336
- Mean Citation Score: 277.504246
- Max Citation Score: 281.1426
- Similarity Product: 237.5059659842849

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test